Biotech News

Newsroom - Neximmune

NexImmune (NEXI)NexImmune2021-02-14 08:03 ESTPartnership

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to NexImmune, its subsidiaries or affiliates. No use of any NexImmune trademark, trade name, or trade dress in this site may be made without the prior written authorization of NexImmune, except to identify the product or services of the company.

© NexImmune. All Rights Reserved. 2021

Open original release

Related news

NEXINexImmune2026-07-09 09:04 EST

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes | NexImmune, Inc.

NEXINexImmune2026-07-09 09:04 EST

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NexImmune, Inc.

NEXINexImmune2026-07-09 09:04 EST

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NexImmune, Inc.

NEXINexImmune2023-10-19 12:00 EST

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting

NEXINexImmune2021-05-04 10:23 EST

Media Inquiries - Neximmune

XOMAXOMA Corporation2026-07-14 13:00 EST

XOMA Royalty Announces Closing of Its Acquisition by Ligand

ARTLArtelo Biosciences2026-07-14 12:47 EST

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

ICCMIceCure Medical2026-07-14 12:32 EST

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

ZBHZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

ENSCEnsysce Biosciences2026-07-14 12:00 EST

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

View all latest news

NexImmune

NexImmune is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

NEXIZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

NEXIZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

NEXIBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

NEXIGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

NEXIMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 0.00 USD
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States